« Mergers & Acquisitions in the United States: A Practical Guide for Non-U.S. Buyers | Main | Innovation by Entrants and Incumbents »
October 12, 2010
The AstraZeneca Judgment: Implications for IP and Regulatory Strategies
Posted by D. Daniel Sokol
David Hull (Covington) explains The AstraZeneca Judgment: Implications for IP and Regulatory Strategies.
ABSTRACT: In a judgment issued on 1 July 2010, the General Court largely upheld the Commission's decision imposing a €60 million fine on AstraZeneca for abusing its dominant position by engaging in certain IP and regulatory strategies aimed at protecting its product against generic competition and parallel imports from other Member States.
October 12, 2010 | Permalink
TrackBack
TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a00d8341bfae553ef0133f4ca8459970b
Listed below are links to weblogs that reference The AstraZeneca Judgment: Implications for IP and Regulatory Strategies:
